Tracer library / [177Lu]Lu-DOTA-exendin-4
[177Lu]Lu-DOTA-exendin-4
Also written as [Lu-177]Lu-DOTA-exendin-4
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated exendin-4 peptide (GLP-1 receptor targeting radiopeptide)
- Target / mechanism
- GLP-1 receptor (GLP-1R) PMID 37265006
- Clinical application
- Insulinoma detection and GLP-1R-targeted radionuclide therapy PMID 37265006
- Theranostic pair
- [68Ga]Ga-DOTA-exendin-4
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | >95% | DOTA-exendin-4 piCHEM, Raaba-Grambach, Austria | 37265006 2023 Mol Pharm DOTA-exendin-4 and DOTA-MI-exendin-4 were labeled with 177Lu by incubating |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- piCHEM
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-exendin-4, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 37265006: 'DOTA-exendin-4, Lys40[Mep((S-)DOTA-Met-Ile-Mal-)]exendin-4'. Stage set/updated at stage 39 from PMID 37265006: 'Biodistribution of [68Ga]Ga-NOTA-exendin-4, [68Ga]Ga-NOTA-MI-exendin-4, [177Lu]Lu-DOTA-exendin-4, and [177Lu]Lu-DOTA-MI-exendin-4 was determined in INS-1 tumor-bearing BALB/c nude mice, and PET/CT was acquired to visualize renal retention and tumor targeting.'.